In the coming decade, many of today’s top-selling biopharmaceuticals will be coming off- patent – creating huge opportunities for generics and biosimilars developers.
Find out how to overcome market access issues by successfully using the Bolar exemption, a provision that exists in different forms across many regionalities and allows for the preparation of generics and biosimilars ahead of originators’ patent expirations.
Don’t miss your free insights into leveraging the Bolar exemption. Download your free white paper from Scrip, presented in partnership with Thermo Fisher Scientific.
Download your free white paper to explore:
• Specificities and challenges of navigating pharmaceutical patents
• The Bolar exemption – definition and patent implications
• Regional differences in Bolar and Bolar-like provisions
• Leveraging these exemptions to accelerate market access for generics and biosimilars